The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLCOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined whether gut microbiome composition relates to clinical outcomes in Chinese patients with advanced non-small cell lung cancer (NSCLC) treated with the anti-PD-1 drug nivolumab.
How was it studied?
Thirty-seven patients from the CheckMate 078 and CheckMate 870 trials gave fecal samples at treatment start, during therapy, and at progression. Samples underwent 16S ribosomal RNA gene sequencing, alongside multicolor flow cytometry of peripheral immune cells.
What did they find?
Responders had higher gut microbiome diversity at baseline that stayed stable during treatment, and high diversity predicted significantly longer progression-free survival. Responders were enriched in Alistipes putredinis, Bifidobacterium longum, and Prevotella copri, while nonresponders showed enrichment of unclassified Ruminococcus. Patients with high microbiome diversity also showed greater peripheral memory CD8+ T cell and natural killer cell subsets.
Why it matters
These findings extend gut microbiome-immunotherapy links, previously shown mainly in Western cohorts, to an East-Asian NSCLC population. Baseline microbiome diversity and composition may help predict which patients respond to anti-PD-1 treatment.